We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lifts Hold on Bluebird Bio’s Gene Therapy Studies
FDA Lifts Hold on Bluebird Bio’s Gene Therapy Studies
The FDA has lifted clinical holds on studies evaluating Bluebird Bio’s LentiGlobin gene therapy for sickle cell disease (SCD) as well as trials of a treatment for a blood disorder that uses the same viral vector.